Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?

Published on May 1, 2020in Microbial Biotechnology5.328
· DOI :10.1111/1751-7915.13536
Liyuan Xiang5
Estimated H-index: 5
(Nanjing Medical University),
Xiao Ding6
Estimated H-index: 6
(Nanjing Medical University)
+ 6 AuthorsFaming Zhang26
Estimated H-index: 26
The efficacy of faecal microbiota transplantation (FMT) in Crohn's disease (CD) remains unclear due to lack of data. This study aimed to assess the value of FMT in treating CD-related clinical targets. The use of FMT for CD as a registered trial (NCT01793831) was performed between October 2012 and December 2017. Seven therapeutic targets included abdominal pain, diarrhoea, hematochezia, fever, steroid-dependence, enterocutaneous fistula and active perianal fistula. Each target was recorded as 1 (yes) or 0 (no) during the long-term follow-up for each patient. The primary outcome was the rate of improvement in each therapeutic target. Overall, 174 patients completed the follow-up. The median follow-up duration was 43 (interquartile range, 28-59) months. The median score of the total targets was 2 (range, 1-4) before FMT, and it decreased significantly at 1, 3, 6, 12, 24 and 36 months after FMT (P < 0.001 respectively). At 1 month after FMT, 72.7% (101/139), 61.6% (90/146), 76% (19/25) and 70.6% (12/17) of patients achieved improvement in abdominal pain, diarrhoea, hematochezia and fever respectively. Furthermore, 50% (10/20) of steroid-dependent patients achieved steroid-free remission after FMT. The present findings indicate that it is important to understand the efficacy of FMT in CD as a targeted therapy, especially for abdominal pain, hematochezia, fever and diarrhoea.
📖 Papers frequently viewed together
5 Citations
1 Citations
8 Authors (Ramit Mahajan, ..., Ajit Sood)
#1Ting Zhang (Nanjing Medical University)H-Index: 13
#2Gaochen Lu (Nanjing Medical University)H-Index: 2
Last. Faming Zhang (Nanjing Medical University)H-Index: 26
view all 14 authors...
Fecal microbiota transplantation (FMT) by manual preparation has been applied to treat diseases for thousands of years. However, this method still endures safety risks and challenges the psychological endurance and acceptance of doctors, patients and donors. Population evidence showed the washed microbiota preparation with microfiltration based on an automatic purification system followed by repeated centrifugation plus suspension for three times significantly reduced FMT-related adverse events....
37 CitationsSource
#1Xiao Ding (Nanjing Medical University)H-Index: 6
#2Qianqian Li (Nanjing Medical University)H-Index: 7
Last. Faming Zhang (Nanjing Medical University)H-Index: 26
view all 8 authors...
Introduction and objective The therapeutic role of fecal microbiota transplantation in ulcerative colitis varies across different reports. This study aims to evaluate the long-term safety and efficacy of a strategy called step-up fecal microbiota transplantation for ulcerative colitis.
51 CitationsSource
#1Nicholas A. Kennedy (University of Exeter)H-Index: 37
#2Graham A. Heap (RD&E: Royal Devon and Exeter Hospital)H-Index: 22
Last. Stephen GoreH-Index: 1
view all 155 authors...
Summary Background Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors that predict primary non-response at week 14 after starting treatment, non-remission at week 54, and adverse events leading to drug withdrawal. Methods The personalised anti-TNF therapy in Crohn's disease study (PANTS) is a prospective observational UK-wide study. We enrolled anti-TNF-naive patients (aged ≥6 ye...
170 CitationsSource
#1Liat Gutin (UCSF: University of California, San Francisco)H-Index: 2
#2Y. Piceno (UCSF: University of California, San Francisco)H-Index: 3
Last. Najwa El-Nachef (UCSF: University of California, San Francisco)H-Index: 9
view all 12 authors...
BackgroundEmerging trials suggest fecal microbiota transplantation (FMT) is a promising treatment for ulcerative colitis; however, there is a paucity of data in Crohn disease (CD).ObjectiveThe obje...
35 CitationsSource
#1Pan Li (Nanjing Medical University)H-Index: 14
#2Ting Zhang (Nanjing Medical University)H-Index: 13
Last. Faming Zhang (Nanjing Medical University)H-Index: 26
view all 8 authors...
Increasing evidence has shown that fecal microbiota transplantation (FMT) could be a promising treatment option for Crohn’s disease (CD). However, the frequency of FMT for CD treatment remains unclear. This study aimed to evaluate the optimal timing for administering the second course of FMT to maintain the long-term clinical effects from the first FMT for patients with CD. Sixty-nine patients with active CD who underwent FMT twice and benefited from the first FMT were enrolled in this study. Cl...
33 CitationsSource
#1Hong-Gang Wang (Nanjing Medical University)H-Index: 9
#2Bota Cui (Nanjing Medical University)H-Index: 16
Last. Faming Zhang (Nanjing Medical University)H-Index: 26
view all 9 authors...
Introduction Fecal microbiota transplantation (FMT) has been used as a potential treatment option for Crohn’s disease (CD). However, there is still lack of safety and efficacy evidence based on large samples of CD undergoing FMT. This study aimed to evaluate the risk factors of adverse event (AE) in the long term and the efficacy of FMT in the short term for patients with CD.
33 CitationsSource
#1Faming Zhang (Nanjing Medical University)H-Index: 26
#2Bota Cui (Nanjing Medical University)H-Index: 16
Last. Daiming Fan (Fourth Military Medical University)H-Index: 88
view all 6 authors...
Fecal microbiota transplantation (FMT) has become a research focus of biomedicine and clinical medicine in recent years. The clinical response from FMT for different diseases provided evidence for microbiota-host interactions associated with various disorders, including Clostridium difficile infection, inflammatory bowel disease, diabetes mellitus, cancer, liver cirrhosis, gut-brain disease and others. To discuss the experiences of using microbes to treat human diseases from ancient China to cur...
74 CitationsSource
#1Chuyan Long (Nanjing Medical University)H-Index: 6
#2Yan Yu (Nanjing Medical University)H-Index: 1
Last. Faming Zhang (Nanjing Medical University)H-Index: 26
view all 8 authors...
This study aimed to evaluate the feasibility, safety, and value of a quick technique for transendoscopic enteral tubing (TET) through mid-gut. A prospective interventional study was performed in a single center. A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transpla...
29 CitationsSource
#1Ting Zhang (Nanjing Medical University)H-Index: 13
#2Jie Xiang (Nanjing Medical University)H-Index: 6
Last. Faming ZhangH-Index: 26
view all 14 authors...
// Ting Zhang 1, * , Jie Xiang 1, * , Bota Cui 1 , Zhi He 1 , Pan Li 1 , Hai Chen 2 , Lijuan Xu 1 , Guozhong Ji 1 , Yongzhan Nie 3 , Kaichun Wu 3 , Daiming Fan 3 , Guangming Huang 1, ** , Jianling Bai 4, ** and Faming Zhang 1, ** 1 Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China 2 Center for Disease Control and Prevention, Wuxi 214000, China 3 State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive Disease...
23 CitationsSource
#1Maja Noman (Katholieke Universiteit Leuven)H-Index: 40
#2Marc Ferrante (Katholieke Universiteit Leuven)H-Index: 59
Last. Gert Van Assche (Katholieke Universiteit Leuven)H-Index: 92
view all 9 authors...
Introduction: Vedolizumab has proven efficacy in inflammatory bowel disease [IBD], but long-term mucosal healing in Crohn's disease [CD], as well as the incidence of colorectal neoplasia in IBD, among patients treated with vedolizumab have not been studied. We aimed to document mucosal healing and to explore the risk of colorectal neoplasia with vedolizumab maintenance therapy. Methods: Surveillance colonoscopy was prospectively scheduled for patients with longstanding ulcerative coltis [UC] or ...
40 CitationsSource
Cited By12
#2Vineet AhujaH-Index: 39
#1Hoon Gil Jo (Wonkwang University)H-Index: 1
#2Geom Seog Seo (Wonkwang University)H-Index: 20
The use of 5-ASA, immunomodulators, biologics, and small molecule drugs are the main treatment for inflammatory bowel disease (IBD), however, fecal microbiota transplantation (FMT) is also drawing attention as a treatment to improve intestinal dysbiosis by transplantaing normal human stool into patients with IBD. FMT demonstrates relatively good effects in inducing clinical remission in IBD, but unlike Clostridium difficile infection, multiple FMT can enhance the clinical effect. There are no re...
#1Sasha R Fehily (University of Melbourne)H-Index: 1
#1Sasha R Fehily (St. Vincent's Health System)H-Index: 1
Last. Michael A. Kamm (University of Melbourne)H-Index: 139
view all 4 authors...
Background null The gastrointestinal microbiota is the key antigenic drive in the inflammatory bowel diseases. Randomized controlled trials (RCTs) in ulcerative colitis have established faecal microbiota transplantation (FMT) as an effective therapy. We have conducted a systematic review to evaluate the efficacy of FMT in Crohn's disease. null Methods null A systematic literature search was performed through to August 2020 [MEDLINE; Embase]. Studies were included if they reported FMT administrat...
1 CitationsSource
PURPOSE OF REVIEW In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD). RECENT FINDINGS Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these trea...
#1Katarzyna Akutko (UWr: University of Wrocław)
#2Andrzej Stawarski (UWr: University of Wrocław)
Inflammatory bowel diseases (IBD), which include Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis of IBD is multifactorial and has not been fully understood. Hence, only symptomatic treatment of these diseases is possible. The current pharmacological treatment has variable efficacy and is associated with the risk of significant side effects. Therefore, there is a constant need t...
#1Qianqian LiH-Index: 7
#2Xiao Ding (Nanjing Medical University)
Last. Faming ZhangH-Index: 26
view all 11 authors...
Background: How to handle patients with anti-tumor necrosis factor (anti-TNF) failure was a common challenge to clinicians in Crohn’s disease (CD). The present study is dedicated to clarifying whether fecal microbiota transplantation (FMT) could be a switch therapy for patients with prior failure of infliximab (IFX) in CD in a long-term observation. Methods: Thirty-six patients with CD who had prior failure of IFX were recruited from January 2013 to December 2019. Patients received the first cour...
#1Esther Caparrós (Universidad Miguel Hernández de Elche)H-Index: 14
#2Reiner Wiest (University of Bern)H-Index: 41
Last. Rubén Francés (Universidad Miguel Hernández de Elche)H-Index: 31
view all 8 authors...
Crohn's disease (CD) is a major form of inflammatory bowel disease characterized by transmural inflammation along the alimentary tract. Changes in the microbial composition and reduction in species diversity are recognized as pivotal hallmarks in disease dynamics, challenging the gut barrier function and shaping a pathological immune response in genetically influenced subjects. The purpose of this review is to delve into the modification of the gut microbiota cluster network during CD progressio...
#1Xiao Ding (Nanjing Medical University)H-Index: 1
#2Xiao-Zhong Yang (Nanjing Medical University)H-Index: 10
Last. Hong-Gang Wang (Nanjing Medical University)H-Index: 9
view all 3 authors...
Abstract Fecal microbiota transplantation (FMT), as an emerging therapy, can be used to treat microbiota related diseases. Progresses in donor screening, washed microbiota preparation, microbiota delivery routes, clinical administrative strategies, and long-term safety are moving FMT forward. Increasing clinical studies, especially those randomized controlled trials about ulcerative colitis and pilot real-word studies about serious inflammatory bowel disease (IBD), have been conducted. This revi...
1 CitationsSource
#1Quan Wen (Nanjing Medical University)H-Index: 1
#2Kangjian Liu (Nanjing Medical University)H-Index: 3
Last. Faming ZhangH-Index: 26
view all 14 authors...
BACKGROUND Colonic transendoscopic enteral tubing (TET) requires double cecal intubation, raising a common concern of how to save cecal intubation time and make the tube stable. We hypothesized that cap-assisted colonoscopy (CC) might reduce the second cecal intubation time and bring potential benefits during the TET procedure. AIM To investigate if CC can decrease the second cecal intubation time compared with regular colonoscopy (RC). METHODS This prospective multicenter, randomized controlled...
1 CitationsSource
#1Luciane de Fátima Caldeira (UFPR: Federal University of Paraná)H-Index: 1
#2Helena H. Borba (UFPR: Federal University of Paraná)H-Index: 11
Last. Roberto Pontarolo (UFPR: Federal University of Paraná)H-Index: 27
view all 6 authors...
Objectives: Current evidence on fecal microbiota transplantation for inflammatory bowel disease is inconclusive. We conducted a systematic review to gather evidence on the efficacy and safety of fecal microbiota transplantation for inflammatory bowel disease. Methods: Systematic searches were conducted in PubMed, Scopus, and Web of Science. Clinical remission was considered as the primary endpoint. Pairwise meta-analyses were performed for the randomized controlled studies (Mantel Haenszel, rand...
8 CitationsSource